Sentinel lymph node detection in early-stage ovarian cancer: a systematic review and meta-analysis

Nuria Agusti, David Viveros-Carreño, Carlos Grillo-Ardila, Nora Izquierdo, Pilar Paredes, Sergi Vidal-Sicart, Aureli Torne, Berta Díaz-Feijoó

ABSTRACT

Background A systematic pelvic and para-aortic lymphadenectomy remains the surgical standard management of early-stage epithelial ovarian cancer. Sentinel lymph node mapping is being investigated as an alternative procedure; however, data reporting sentinel lymph node performance are heterogeneous and limited.

Objective This study aimed to evaluate the detection rate and diagnostic accuracy of sentinel lymph node mapping in patients with early-stage ovarian cancer.

Methods A systematic search was conducted in Medline (through PubMed), Embase, Scopus, and the Cochrane Library. We included patients with clinical stage I–II ovarian cancer undergoing a sentinel lymph node biopsy and a pelvic and para-aortic lymphadenectomy as a reference standard. We conducted a meta-analysis for the detection rates and measures of diagnostic accuracy and assessed the risk of bias using the Quality Assessment of Diagnostic Accuracy Studies 2 tool. The study was registered in the International Prospective Register of Systematic Reviews (PROSPERO) with identifying number CRD42022351497.

Results After duplicate removal, we identified 540 studies, 18 were assessed for eligibility, and nine studies including 113 patients were analyzed. The pooled detection rates were 93.3% per patient (95% CI 77.8% to 100%; I²=74.3%, p<0.0001), and the sentinel lymph node technique correctly identified 11 of 12 patients with lymph node metastases, with a negative predictive value per patient of 100% (95% CI 97.6% to 100%; I²=0%). The combination of indocyanine green and 99mTc-albumin nanocolloid had the best detection rate (100% (95% CI 94% to 100%; I²=0%)) when injected into the utero-ovarian and infundibulo-pelvic ligaments.

Conclusion Sentinel lymph node biopsy in early-stage ovarian cancer showed a high detection rate and negative predictive value. The utero-ovarian and infundibulo-pelvic injection using the indocyanine green and technetium-99 combination could increase sentinel lymph node detection rates. However, given the limited quality of evidence and the small number of reports, results from ongoing trials are awaited before its implementation in routine clinical practice.

INTRODUCTION

Ovarian cancer is mainly diagnosed at an advanced stage (International Federation of Gynecology and Obstetrics (FIGO) stage III or IV) and only 20% to 30% of patients with ovarian cancer are diagnosed with clinically early-stage (FIGO stage I–II) disease at initial evaluation. A comprehensive staging surgery, including a systematic pelvic and para-aortic lymphadenectomy, remains the standard surgical management of patients with early-stage epithelial ovarian cancer to determine the prognosis and need for adjuvant treatment. However, the incidence of lymph node involvement is about 15–20%. Performing a lymphadenectomy is an invasive and laborious technique, associated with intra-operative and post-operative morbidity, and has a negative impact on the quality of life. Additionally, no evidence suggests a possible therapeutic value of systematic lymphadenectomy.
Over the past decade, sentinel lymph node (SLN) mapping has emerged as an alternative technique to identify lymph node metastases while reducing the surgical morbidity associated with systematic lymphadenectomies. The SLN mapping technique has proved accurate in other gynecological cancers.\(^5\text{-}^9\) Nevertheless, its application in ovarian cancer is challenging since the tracer injection technique and the ovarian lymphatic drainage are more complex than for other gynecological tumors.

Few studies with a limited number of patients have been published and heterogeneously reported the feasibility of ovarian SLN mapping.\(^9\text{-}^{11}\) Some aspects remain to be resolved regarding the use of tracers, the injection site, the detection rate according to the technique used, and the diagnostic accuracy. A detailed evaluation of the factors and the consequences of applying different methods of SLN detection and why variation might occur in early-stage ovarian cancer has not been assessed. The objectives of this systematic review and meta-analysis were to assess the detection rate and diagnostic accuracy of SLN mapping in the staging of patients with early-stage ovarian cancer who had undergone full pelvic and para-aortic lymphadenectomy as the reference standard.

**METHODS**

The protocol was prospectively registered with the International Prospective Register of Systematic Reviews (PROSPERO) under identifying number CRD42022351497, and the systematic review was conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA).\(^12\)

**Eligibility Criteria**

Inclusion criteria were studies performing the SLN mapping technique in patients diagnosed with early-stage (FIGO I-II) ovarian cancer and reporting the detection rate and diagnostic accuracy who had undergone full pelvic and para-aortic lymphadenectomy. All ages, histological tumor types, grades, surgical access, and all sentinel node detection techniques were allowed.

We excluded patients with benign ovarian pathology, borderline tumors or absence of ovarian pathology, non-human articles, case series, video articles, review articles, editorial letters, and abstracts. When two or more manuscripts were published using the same data source, only the most complete manuscript was included.

**Information Sources and Search Strategy**

A systematic literature search was performed using Medline (through PubMed), Embase, Scopus, and Cochrane Library from inception to September 1, 2022. The search strategy is reported in the supplementary material (Online supplemental appendix table 1). The electronic search was supplemented by evaluating the reference lists of the included studies. We limited articles to the English, Spanish, Italian, and French language, but search strategies were created with English terms only.

**Study Selection and Data Collection Process**

Rayyan software (Qatar Computing Research Institute, HBKU, Doha, Qatar) was used for the title and abstract screening for eligibility and, after the removal of duplicates, all citations were reviewed independently by two reviewers (NA and NI) at two stages (titles and abstract, and full-text review). Disagreements were resolved by discussion between the reviewers. Reasons for exclusion were recorded.

Data collection included: author, publication year, country, sample size, study period, type of surgery, surgical approach, reference standard, SLN technique (injection site, type of tracer, timing, and dose), SLN outcomes (diagnostic accuracy and detection rate), SLN ultrastaging performance, and adverse events. The corresponding author was contacted to obtain missing data, if needed.

We will provide our data for independent analysis by a selected team or for additional data analysis or for the reproducibility of this study in other centers, if such is requested.

**Outcomes**

The primary outcomes were the overall detection rate of SLN defined as the proportion of individuals with at least one SLN detected, and the diagnostic accuracy of SLN for the staging of patients with ovarian cancer who had undergone complete pelvic and para-aortic lymphadenectomy as a reference standard. The secondary outcome was to analyze factors related to the SLN mapping detection rate and diagnostic accuracy. The specific detection rate was analyzed depending on (1) tracers used, (2) injection site, and (3) type of surgery.

**Assessment of Risk of Bias**

The risk of bias were assessed independently by two reviewers (NA and DV-C) using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool.\(^13\) The risk of bias was assessed for the following domains: patient selection, index test, reference standard, and flow and timing. The risk of bias was judged as ‘low’, ‘high’, or ‘unclear’ in each domain.

**Analysis and Data Synthesis**

Data were presented as means or medians for quantitative variables based on the distribution of the data, which has been tested using the Smirnov–Kolmogorov test. Categorical variables were represented using relative frequencies (percentages). P values were reported using the \(\chi^2\) or Fisher’s exact test in categorical variables according to the sample size in each subgroup. We used Stata 14.0 (StataCorp, College Station, Texas, USA) and JBI SUMARI (The University of Adelaide, Australia) to conduct the meta-analysis. Given the expected heterogeneity, a random-effects model was used. We calculated predictive value estimates from the extracted data.

**RESULTS**

**Study Selection**

The initial search identified 717 manuscripts. Seven manuscripts were identified via registries and manual searching, and citation tracking. After removing duplicate manuscripts 540 studies were evaluated. Following title and abstract screening, 18 articles were selected for full-text screening. Of the 18 full-text articles, nine were excluded\(^{14}\text{-}^{22}\) and finally, nine articles were included.\(^{23}\text{-}^{31}\) Reasons for exclusion are outlined in (Online supplemental appendix table 2). The PRISMA flow diagram shows the complete review process from the original search to the final selection (Figure 1).
A total of 113 patients were included. The studies were conducted between 2014 to 2021. The median age was reported in seven studies, ranging from 45 to 57. Median body mass index was reported in five studies, ranging from 20.5 to 25.2 kg/m². Six studies were considered observational, and three were clinical trials. Five studies included a total of 58 patients without ovarian cancer, and those patients were excluded from the analysis (3 patients with cervical cancer, 1 with a concomitant endometrial cancer, 10 with borderline ovarian tumors, and 44 patients with benign tumors). The most common tracer used in the studies was indocyanine green (ICG) in 61 patients (54%), followed by the 99mTc in 51 patients (45.1%) and blue dye in 23 patients (20.4%). The tracers were used either as a single agent or in combination. The main characteristics of the included studies are presented in Table 1.

### Risk of Bias of Included Studies
The quality assessment of the included studies is presented in Online supplemental appendix figure 1. Most studies were at low risk of bias in the patient selection, index test, and reference standard domains. Three studies were at unclear risk of bias in the patient selection domain because consecutive recruitment was not well specified. One study was also at an unclear risk of bias in the standard reference domain because it was unclear if a complete systematic lymphadenectomy was performed.

### SYNTHESIS OF RESULTS

#### Overall SLN Detection Rate
At least one SLN was detected in 94 (83.2%) of 113 patients. The SLN detection rate was 93.3% (95% CI 77.8% to 100%; p<0.0001; $I^2=74.3\%$) and ranged from 27% to 100% in individual studies (Figure 2). Seven studies including 76 patients described the location drainage: in 67 patients (88.2%) a SLN was detected in the aortic region (in 32 patients (42.1%) the drainage was only aortic and in 35 (46.1%) the drainage was present in pelvic and aortic regions). In 9 (11.8%) patients, only pelvic SLN were detected.

#### Diagnostic Accuracy Analysis
The SLN technique correctly identified 11 (91.7%) of 12 patients with lymph node metastases. Para-aortic lymph node involvement was reported in nine patients, pelvic involvement in two patients, and both pelvic and aortic involvement in one patient. The pooled negative predictive value per patient was 100% (95% CI 97.6% to 100%; p=0.97; $I^2=0\%$) (Figure 3). An ultrastaging protocol was used in 5 (41.7%) of 12 patients with lymph node metastases, finding two SLNs with isolated tumor cells and four SLNs with macro-metastasis.

#### Type of Tracers
ICG alone was used in three studies, including 43 patients (38%), and blue dye alone in one study with 11 patients (9.7%), showing a detection rate of 90.5% (95% CI 61.5% to 100%);
Original research

I²=65.9%) and 100% (95% CI 84.9% to 100%; I²=0%), respectively (Figure 4).

99mTc was used alone in nine patients (8%) 26 with a detection rate of 88.9% (95% CI 58.2% to 100%; I²=0%) and in combination with patent blue in 20 patients (17.7%) 25 26 29 or in combination with ICG in 30 patients (26.5%), 24 30 with a detection rate of 80.9% (95% CI 22.1% to 100%; I²=82.5%) and 100% (95% CI 94% to 100%; I²=0%), respectively. There was no statistically significant difference when the heterogeneity source was explored by tracer type (p=0.54). The waiting time between the injection of the marker and the detection of SLN reported by most studies averaged 10–15 min (Table 1), except for those studies that only used ICG alone, which followed the migration of the tracer immediately after injection.

### Injection Site and Surgical Technique

The most used injection site was the infundibulo-pelvic and utero-ovarian ligament (if no previous hysterectomy had been performed) in eight studies, including 105 patients (92.2%), on the ipsilateral side of the tumor, or bilaterally when both ovaries were involved. However, other injection sites were described: one study, 26 including three patients (2.7%), performed the tracer injection on the ovarian cortex; and another study 28 including five patients (4.4%), used the hilum of the ovary, the broad ligament, and the ovarian parenchyma as the site of injection.

The pooled SLN detection rate when the injection site was in the ovarian ligaments was 92.9% (95% CI 73.7% to 100%; I²=80.5%) in comparison with other injection sites with a pooled detection rate

### Table 1 Characteristics of the included studies

<table>
<thead>
<tr>
<th>Author, year; country</th>
<th>Sample size</th>
<th>Study period</th>
<th>Type of surgery</th>
<th>Surgical approach</th>
<th>Injection site</th>
<th>Tracer used and dose</th>
<th>Time between injection and detection</th>
<th>SLN ultrastaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kleppe et al 25 2014; Netherlands</td>
<td>5</td>
<td>October 2012 to June 2014</td>
<td>PSS</td>
<td>LPT</td>
<td>UO and IP ligaments</td>
<td>0.2–0.5 mL of Tc-99m albumin nanocolloid and blue dye (each injection)</td>
<td>15 min</td>
<td>Yes</td>
</tr>
<tr>
<td>Hassanzadeh et al 26 2016; Iran</td>
<td>13</td>
<td>January 2010 to October 2014</td>
<td>PSS</td>
<td>LPT</td>
<td>UO and IP ligaments (n=10); Cortex (n=3)</td>
<td>0.2 mL of Tc-99m phytate+blue dye (each injection)</td>
<td>10 min</td>
<td>NS</td>
</tr>
<tr>
<td>Angelucci et al 27 2016; Italy</td>
<td>5</td>
<td>April 2016 to May 2016</td>
<td>PSS</td>
<td>MIS</td>
<td>Hilum of ovary</td>
<td>0.5–1 mL of ICG, (1.25 mg/mL)</td>
<td>2 min</td>
<td>NS</td>
</tr>
<tr>
<td>Buda et al 28 2017; Italy</td>
<td>7</td>
<td>NR</td>
<td>PSS</td>
<td>MIS</td>
<td>UO and IP ligaments</td>
<td>0.5 to 1 mL of ICG (1.25 mg/mL)</td>
<td>Real time</td>
<td>NS</td>
</tr>
<tr>
<td>Uccella et al 23 2019; Italy</td>
<td>31</td>
<td>March 2018 - ongoing</td>
<td>PSS and DSS</td>
<td>MIS</td>
<td>UO and IP ligaments (after adnexectomy)</td>
<td>2 mL of ICG (1.25 mg/mL)</td>
<td>5–20 min</td>
<td>Yes</td>
</tr>
<tr>
<td>Lago et al 24 2018; Spain</td>
<td>10</td>
<td>March 2017 to February 2018</td>
<td>PSS and DSS</td>
<td>MIS+LPT</td>
<td>UO and IP ligaments (after adnexectomy)</td>
<td>0.2 mL of Tc-99m albumin colloid (37 MBq) + 0.5 mL of ICG (1.25 mg/mL)</td>
<td>15 min</td>
<td>Yes</td>
</tr>
<tr>
<td>Lago et al 29 2020; Spain</td>
<td>20</td>
<td>March 2018 to July 2019</td>
<td>PSS and DSS</td>
<td>MIS+LPT</td>
<td>UO and IP ligaments (after adnexectomy)</td>
<td>0.2 mL of Tc-99m albumin colloid (37 MBq) + 0.5 mL of ICG (1.25 mg/mL)</td>
<td>15 min</td>
<td>Yes†</td>
</tr>
<tr>
<td>Laven et al 29 2021; Netherlands</td>
<td>11</td>
<td>NR</td>
<td>PSS and DSS</td>
<td>LPT</td>
<td>UO and IP ligaments (after adnexectomy)</td>
<td>0.15 mL of Tc-99m albumin nanocolloid (20 MBq) + 0.2 mL blue dye</td>
<td>15 min</td>
<td>Yes</td>
</tr>
<tr>
<td>Guerra 27 2021; Venezuela</td>
<td>28</td>
<td>June 2016 to November 2019</td>
<td>DSS</td>
<td>LPT</td>
<td>UO and IP ligaments</td>
<td>0.5 mL of Isosulfan (UO ligament) + 2 mL (IP ligament)</td>
<td>15 min</td>
<td>NS</td>
</tr>
</tbody>
</table>

*Refers only to patients with malignant ovarian cancer. †Ultrastaging protocol was applied a second time.

DSS, delayed or restaging surgery; ICG, indocyanine green; IP, Infundibulo-pelvic; LPT, laparotomy; MIS, minimal invasive surgery; NR, not reported; NS, not specified; PSS, primary staging surgery; SLN, sentinel lymph node; UO, utero-ovarian.
of 88.5% (95% CI 42.6% to 100%; I²=7.4%). This difference was not statistically significant (p=0.61) (Online supplemental appendix figure 2).

In 33 (29.2%) patients the injection was performed in the ovarian ligaments with the mass still in situ25-27 and, in 47 (41.6%) patients in the ovarian ligaments stumps of the removed adnexa, just after the frozen section report of malignancy. Lastly, in 25 (22.1%) patients, the injection was performed in the ovarian ligament stumps during a re-staging intervention surgery. The pooled detection rate was 98.9% (95% CI 89.8% to 100%; I²=0%), 89.7% (95% CI 58.3% to 100%; I²=84.7%), and 78.9% (95% CI 6.7% to 100%; I²=95%), respectively (Online supplemental appendix figure 3). There was no statistically significant difference when the heterogeneity source was explored (p=0.72).

Complications
No complications were reported for the tracer injection. Three studies23 24 30 described a vascular injury related to the lymphadenectomy and not the SLN dissection.

DISCUSSION
Summary of Main Results
SLN mapping was associated with a high detection rate (93.3%) and negative predictive value (100%) in patients with early-stage ovarian cancer. The individual detection rate from the included studies varied widely, ranging from 27% to 100%. The combination of both tracers ICG and 99mTc resulted in the best detection rate when injected into the ovarian ligaments before the adnexectomy, as was blue dye, but with few patients. The 92% pooled detection rate...

Figure 2  Forest plot showing the overall detection rate.

Figure 3  Forest plot showing the negative predictive value.
### A Indocyanine green and [99mTc]Tc-albumin nanocolloid

<table>
<thead>
<tr>
<th>Study</th>
<th>Events</th>
<th>Total</th>
<th>Weight, F-T, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lago 2020</td>
<td>20</td>
<td>20</td>
<td>66.13% [0.916, 1.000]</td>
</tr>
<tr>
<td>Lago 2018</td>
<td>10</td>
<td>10</td>
<td>33.87% [0.835, 1.000]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>30</td>
<td>30</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\chi^2=0$, $df=1$ ($P=0.8201$) $I^2=0$

### B [99mTc]Tc-albumin nanocolloid

<table>
<thead>
<tr>
<th>Study</th>
<th>Events</th>
<th>Total</th>
<th>Weight, F-T, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hassanzadeh 2016</td>
<td>8</td>
<td>9</td>
<td>100% [0.582, 1.000]</td>
</tr>
</tbody>
</table>

Total (95% CI) 8 9

Heterogeneity: $\chi^2=0$, $df=0$ ($P=1$) $I^2=0$

### C [99mTc]Tc-albumin nanocolloid and blue dye

<table>
<thead>
<tr>
<th>Study</th>
<th>Events</th>
<th>Total</th>
<th>Weight, F-T, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hassanzadeh 2016</td>
<td>4</td>
<td>4</td>
<td>31.14% [0.611, 1.000]</td>
</tr>
<tr>
<td>Kleppe 2014</td>
<td>5</td>
<td>5</td>
<td>32.53% [0.683, 1.000]</td>
</tr>
<tr>
<td>Laven 2021</td>
<td>3</td>
<td>11</td>
<td>36.34% [0.044, 0.657]</td>
</tr>
</tbody>
</table>

Total (95% CI) 12 20

Heterogeneity: $\chi^2=13.06$, $df=2$ ($P=0.0015$) $I^2=82.5$

### D Blue dye

<table>
<thead>
<tr>
<th>Study</th>
<th>Events</th>
<th>Total</th>
<th>Weight, F-T, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guerra 2021</td>
<td>11</td>
<td>11</td>
<td>100% [0.849, 1.000]</td>
</tr>
</tbody>
</table>

Total (95% CI) 11 11

Heterogeneity: $\chi^2=0$, $df=0$ ($P=1$) $I^2=0$

### E Indocyanine green

<table>
<thead>
<tr>
<th>Study</th>
<th>Events</th>
<th>Total</th>
<th>Weight, F-T, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angelucci 2016</td>
<td>5</td>
<td>5</td>
<td>26.14% [0.683, 1.000]</td>
</tr>
<tr>
<td>Buda 2016</td>
<td>7</td>
<td>7</td>
<td>30.06% [0.768, 1.000]</td>
</tr>
<tr>
<td>Uccella 2019</td>
<td>21</td>
<td>31</td>
<td>43.8% [0.501, 0.832]</td>
</tr>
</tbody>
</table>

Total (95% CI) 33 43

Heterogeneity: $\chi^2=6.4$, $df=2$ ($P=0.0407$) $I^2=65.9$

---

**Figure 4**  Forest plot showing the detection rate depending on the type of tracers used.
rate is comparable with that observed in other gynecological neoplasia like cervical or endometrial cancer.5 7 8

Results in the Context of Published Literature
SLN mapping in patients with early-stage ovarian cancer is an experimental procedure in which multiple tracers, injection methods, and technical procedures have been described. No previous meta-analysis on SLN detection in patients with early-stage ovarian cancer has been previously published. Some reviews3–11 have included a miscellany of benign and malignant pathology. Only one meta-analysis regarding SLN of the ovary by Ataei et al was previously published,11 but included information based on an abstract data, and analyzed a widely heterogeneous population, such as patients with both malignant and benign ovarian tumors, other concomitant gynecological tumors, or patients operated for other reasons. This broad selection of patients might lead to a biased conclusion.

According to the two main lymphatic pathways, most of the studies performed a tracer injection into the ovarian ligaments showing a high pooled detection rate. Other injection sites have been described, such as the ovarian cortex, but it might be risky due to a possible tumor spillage and dissemination.36 We found a substantial heterogeneity among used tracers. The interest in use of ICG as a single agent is its easy detection. However, the combined use of ICG and 99mTc has been relatively underexplored when results are just based on one study group. 24 30 Interestingly, the ICG and 99mTc combination has been relatively underexplored when considering other neoplasias32 and may enhance the advantages of both tracers in patients with ovarian cancer.33

Another controversial issue is the optimal time to inject the tracer. Up to five studies25–28, 31 achieved a high detection rate of 98.9% injecting the tracer into the ovarian ligaments prior to the tumor removal, hypothetically the ideal injection time since the lymphatic pathways have not yet been disrupted. Alternatively, four studies23 24 29 30 assessed the feasibility of performing a tracer injection into the ovarian ligaments’ stumps, right after the adnexa removal and malignancy confirmation, to avoid an unnecessary injection when the intra-operative pathology shows benign histology. In this setting, the pooled detection rate was lower, showing conflicting results among the studies. This discrepancy could be related to the surgical technique and the different tracers used among the studies. Additionally, the high detection rate presented by Lago et al could be due to the fact that the injection was performed deep and close to the dorsal/lateral parametrium,34 resulting in tracing uterine lymphatic pathways and obtaining a very high pelvic detection rate.

Performing SLN mapping in patients undergoing a restaging surgery is controversial since the pathways of lymphatic vessels might be altered and the SLN should reflect the distorted manipulated and fibrous tissue. Lago et al30 argue that lymphatic drainage still persists after the adnexectomy in a unidirectional flow from the ovarian ligament stumps to the para-aortic and pelvic fields, respectively. However, Uccella et al and Laven et al showed more discouraging results.23 29

As reported in the literature,35, 36 the para-aortic route was the main lymphatic spread. Conversely, the detection rate in the pelvic region was lower. A possible reason could be the retroperitoneal pelvic extravasation when injecting the tracer, hindering subsequent SLN detection. In order to increase pelvic detection rate, Uccella et al19 proposed to assess the concordance between two theoretically different lymphatic pathways by performing a cervical injection with ICG and utero-ovarian ligament injection with blue dye in patients with endometrial cancer. Interestingly, they found the same pelvic SLN in all cases with both tracers, suggesting that the two injection sites might be equivalent.

The pooled negative predictive value was 100%. This is probably the best estimate to consider regarding SLN diagnostic accuracy since the main expected benefit of SLN clinical application in patients with early-stage ovarian cancer is to avoid unnecessary systematic lymphadenectomy in node-negative cases. The missing metastasis was in a patient that had a metastatic lymph node in the aortic region in whom no para-aortic SLN was identified, and a pelvic SLN was found as negative.24 As already described in other cancer sites,37 applying a well-defined SLN mapping algorithm going beyond the removal of only the detected SLN could increase the sensitivity and decrease the false-negative rate. Therefore, it seems essential to define the ovarian lymphatic drainage pathways as well as a specific algorithm, such as performing a lymphadenectomy in cases of no drainage in a specific anatomical region.28

The MELISA trial,35 SELLY trial,40 and TRSGO-SLN-00541 are three ongoing trials that aim to evaluate the detection rate and diagnostic accuracy of the SLN in early-stage ovarian cancer (Online supplemental appendix table 2c).

Strengths and Weaknesses
The strength of this review is the rigorous methodology applied. It has a registered protocol, and was conducted following the guidelines for reporting systematic reviews. Strict selection criteria focused only on the population with early-stage ovarian cancer, and an adequate reference standard with the pelvic and para-aortic lymph node dissection was used to reduce the risk of biases and heterogeneity. Finally, published tools to assess methodological quality and risk of bias were considered for analyses.

We recognize several limitations, such as the inclusion of different types of studies and the limited sample size from only nine included manuscripts, limiting the conclusions regarding diagnostic accuracy, and the subgroup analysis to draw consistent conclusions. Moreover, we found substantial clinical heterogeneity among the studies regarding the tracers used and the technique for injection.

Implications for Practice and Further Research
The SLN technique is considered the standard of care for other gynecologic cancers. Our review showed that SLN mapping resulted in a high detection rate and negative predictive value in patients with early-stage ovarian cancer and provides information on which tracer, injection site, and type of surgery performed better. Although evidence is still limited, this study synthesizes the current SLN data in patients with ovarian cancer and might be a reference for the design of future studies before considering the technique in a clinical setting.

CONCLUSIONS
SLN mapping in patients with early-stage ovarian cancer showed a high detection rate and negative predictive value. SLN mapping is a surgical procedure under investigation in
Original research

the management of select patients with early-stage ovarian cancer. However, given the low quality of available evidence, results from future prospective trials are awaited before its implementation in routine clinical practice.

Author affiliations
1Gynecology Oncology Unit, Instituto Clinic of Gynecology, Obstetrics, and Neonatology, Hospital Clinic of Barcelona, Barcelona, Spain
2Department of Gynecologic Oncology, Instituto Nacional de Cancerologia, Bogotá, Colombia, Bogota, Colombia
3Department of Nuclear Medicine, Hospital Clinic de Barcelona, Barcelona, Spain
4Department of Nuclear Medicine, Hospital Clinic of Barcelona, Barcelona, Spain
5Department of Gynecology and Obstetrics, Universidad Nacional de Colombia - Sede Bogotá, Bogota, Colombia
6Department of Gynecology and Obstetrics, Universidad Nacional de Colombia - Sede Bogotá, Bogota, Colombia
7IDIBAPS, Barcelona, Spain
8Department of Gynecology and Obstetrics, Universidad Nacional de Colombia - Sede Bogotá, Bogota, Colombia
9Department of Nuclear Medicine, Hospital Clinic de Barcelona, Barcelona, Spain
10IDIBAPS, Barcelona, Spain
11Faculty of Medicine, University of Barcelona, Barcelona, Spain

Correction notice This article has been corrected since it was first published. A duplication error in the Objective section of the Abstract has been fixed.

Twitter Nuria Agusti @nagustiga and Berta Díaz-Feijo @Berdiazfeijo

Contributors NA is the principal investigator, designed the study, reviewed the literature, collected and analyzed data, and wrote the paper. DV-C contributed to conceptualizing the project, independently screening and assessing all studies, and edited the manuscript. CG contributed to conceptualizing the project and statistical assistance. NI contributed to independently screening and assessing all studies, and edited the manuscript. PP and SV-S contributed to conceptualizing the project and edited the manuscript. AT and BD-F contributed to conceptualizing the project, consulted for clinical expertise, reviewed the data and analyses, and edited the manuscript. NA is the guarantor and accepts full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

ORCID iDs
Nuria Agusti http://orcid.org/0000-0002-1165-0661
David Viveros-Carrero http://orcid.org/0000-0001-9395-0627
Sergi Vidal-Sicart http://orcid.org/0000-0002-6303-3686
Aureli Tome http://orcid.org/0000-0003-4700-9507
Berta Díaz-Feijo http://orcid.org/0000-0002-6451-1817

REFERENCES


